Skip to main content
SpringerLink
Log in

Chronic inflammation and cancer in various organ systems

  • Chapter
Cancer and Inflammation

Part of the book series: Progress in Inflammation Research ((PIR))

  • 142 Accesses

Abstract

Cancer is one of the leading causes of mortality and morbidity worldwide. The Global Burden of Disease Study estimated that, in 1990, 6 million out of 50.5 million deaths worldwide (12%) were attributable to cancer [1]. Among the top 30 causes of deaths worldwide that year, lung cancer, stomach cancer, liver cancer, colorectal cancer, esophageal cancer, and breast cancer ranked 10th, 14th, 22nd, 24th, 26th and 29th, respectively. In 1999, as per the World Health Organization mortality data, 23% of the total deaths in the United States occurred from cancer [2]. The United Kingdom and Japan reported similar rates at 24% and 30%, respectively. Mortality data from other countries are available at the World Health Organization website (http://www.who.int/en).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Murray CJL, Lopez AD (1997) Mortality by cause for eight regions of the world: Glob-al Burden of Disease Study. Lancet 349: 1269–1276

    PubMed  CAS  Google Scholar 

  2. http://www-depdb.iarc.fr/who/menu.htm

  3. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420: 860–867

    PubMed  CAS  Google Scholar 

  4. O’Byrne KJ, Dalgleish AG (2001) Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer 85: 473–483

    PubMed  Google Scholar 

  5. Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357: 539–545

    PubMed  CAS  Google Scholar 

  6. Dvorak HF (1986) Tumors: wounds that do not heal. Similarities between tumor stro-ma generation and wound healing. N Engl J Med 315: 1650–1659

    PubMed  CAS  Google Scholar 

  7. Williams MP, Pounder RE (1999) Helicobacter pylori: From the benign to the malignant. Am J Gastroenterol 94 (Suppl): S11–S16

    PubMed  CAS  Google Scholar 

  8. Kuipers EJ, Uyterlinde AM, Pena AS, Roosendaal R, Pals G, Nelis GF, Festen HP, Meuwissen SG (1995) Long-term sequelae of Helicobacter pylori gastritis. Lancet 345: 1525–1528

    PubMed  CAS  Google Scholar 

  9. International Agency for Research on Cancer Schistosomes, liver flukes and Helicobac-ter pylori (1994) IARC monographs on the evaluation of carcinogenic risks to humans, Vol. 61. International Agency for Research on Cancer, Lyon

    Google Scholar 

  10. Parkin DM, Bray FI, Devesa SS (2001) Cancer burden in the year 2000. The global picture. Eur J Cancer 37: S4–566

    PubMed  Google Scholar 

  11. Howson CP, Hiyama T, Wynder EL (1986) The decline of gastric cancer: epidemiology of an unplanned triumph. Epidemiol Rev 8:1–27

    PubMed  CAS  Google Scholar 

  12. Kelley JR, Duggan JM (2003) Gastric cancer epidemiology and risk factors. J Clin Epidemiol 56: 1–9

    PubMed  Google Scholar 

  13. Parkin DM, Pisani P, Ferlay J (1993) Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 54: 594–606

    PubMed  CAS  Google Scholar 

  14. Kelley JR, Duggan JM (2003) Gastric cancer epidemiology and risk factors. [Review]. J Clin Epidemiol 56: 1–9

    PubMed  Google Scholar 

  15. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK (1991) Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 325: 1127–1131

    PubMed  CAS  Google Scholar 

  16. The Eurogast Study Group (1993) An international association between Helicobacter pylori infection and gastric cancer. Lancet 341: 1359–1362

    Google Scholar 

  17. Sipponen P, Kosunen TU, Valle J, Riihela M, Seppala K (1992) Helicobacter pylori infection and chronic gastritis in gastric cancer. J Clin Pathol 45: 319–323

    PubMed  CAS  Google Scholar 

  18. Kikuchi O, Wada T, Nakajima T, Nishi T, Kobayashi O, Konishi T, Inaba Y (1995) Serum anti-Helicobacter pylori antibody and gastric carcinoma among young adults. Cancer 75: 2789–2793

    PubMed  CAS  Google Scholar 

  19. Asaka M, Kimura T, Kato M, Kudo M, Miki K, Ogoshi K, Kato T, Tatsuta M, Graham DY (1994) Possible role of Helicobacter pylori infection in early gastric cancer development. Cancer 73: 2691–2694

    PubMed  CAS  Google Scholar 

  20. Banatvala N, Mayo K, Megraud F, Jennings R, Deeks JJ, Feldman RA (1993) The cohort effect and Helicobacter pylori. J Infect Dis 168: 219–221

    CAS  Google Scholar 

  21. Webb PM, Forman D (1995) Helicobacter pylori as a risk factor for cancer. Baillieres Clin Gastroenterol 9: 563–582

    PubMed  CAS  Google Scholar 

  22. Parsonnet J, Forman D (2004) Helicobacter pylori and gastric cancer. JAMA 291: 187–194

    Google Scholar 

  23. Danesh J (1999) Helicobacter pylori and gastric cancer; systematic review of epidemiological studies. Aliment Pharmacol Then 13: 851–856

    CAS  Google Scholar 

  24. Eslick GD, Lim LL, Byles JE, Xia HH, Talley NJ (1999) Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Am J Gastroenterol 94: 2373–2379

    PubMed  CAS  Google Scholar 

  25. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ (2001) Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345: 784–789

    PubMed  CAS  Google Scholar 

  26. Uemura N, Mukai T, Okamoto S, Yamaguchi S, Mashiba H, Taniyama K, Sasaki N, Haruma K, Sumi K, Kajiyama G (1997) Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prey 6: 639–642

    CAS  Google Scholar 

  27. Isaacson P, Wright DH (1983) Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B cell lymphoma. Cancer 52: 1410–1416

    PubMed  CAS  Google Scholar 

  28. Morgner A, Bayerdorffer E, Neubauer A, Stolte M (2000) Malignant tumors of the stomach. Gastric mucosa-associated lymphoid tissue lymphoma and Helicobacter pylori. Gastroenterol Clin North Am 29: 593–607

    CAS  Google Scholar 

  29. Wotherspoon AC, Ortiz Hidalgo C, Falzon MR, Isaacson PG (1991) Helicobacter pylori-associated gastritis and primary B cell gastric lymphoma. Lancet 338: 1175–1176

    PubMed  CAS  Google Scholar 

  30. Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA, Jellum E, Orentreich N, Vogelman JH, Friedman GD (1994) Helicobacter pylori infection and gastric lymphoma. N Engl j Med 330: 1267–1271

    PubMed  CAS  Google Scholar 

  31. Doglioni C, Wotherspoon AC, Moschini A, De Boni M, Isaacson PG (1992) High incidence of primary gastric lymphoma in northeastern Italy. Lancet 339: 834–835

    PubMed  CAS  Google Scholar 

  32. Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, De Boni M, Isaacson PG (1993) Regression of primary low-grade B cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 342: 575–577

    PubMed  CAS  Google Scholar 

  33. Cammarota G, Montalto M, Tursiet A, Vecchio FM, Fedeli G, Gasbarrini G (1995) Helicobacter pylori reinfection and rapid relapse of low-grade B-cell gastric. Lancet 345: 192

    PubMed  CAS  Google Scholar 

  34. Bayerdorffer E, Neubauer A, Rudolph B, Thiede C, Lehn N, Eidt S, Stolte M (1995) Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. Lancet 345: 1591–1594

    PubMed  CAS  Google Scholar 

  35. Morgner A, Miehlke S, Fischbach W, Schmitt W, Muller-Hermelink H, Greiner A, Thiede C, Schetelig J, Neubauer A, Stolte M et al (2001) Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection. J Clin Oncol 19: 2041–2048

    PubMed  CAS  Google Scholar 

  36. Morgner A, Lehn N, Andersen LP, Thiede C, Bennedsen M, Trebesius K, Neubauer B, Neubauer A, Stolte M, Bayerdorffer E (2000) Helicobacter heilmannii-associated pri-mary gastric low-grade MALT lymphoma: complete remission after curing the infection. Gastroenterology 118: 821–828

    PubMed  CAS  Google Scholar 

  37. Du MQ (2002) Gastric MALT lymphoma: from aetiology to treatment. Lancet Oncol 3: 97–104

    PubMed  CAS  Google Scholar 

  38. Seaberg EC, Belle SH, Beringer KC, Schivins JL, Detre KM (1999) Liver transplantation in the United States from 1987–1998: Updated results from the Pitt-UNOS liver transplant registry. In: JM Cecka, PI Terasaki (eds): Clinical transplants 1998. UCLA Tissue Typing Laboratory, Los Angeles, 17–37

    Google Scholar 

  39. Wasley A, Alter MJ (2000) Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 20: 1–16

    PubMed  CAS  Google Scholar 

  40. World Health Organization (1999) Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 6: 35–47

    Google Scholar 

  41. Wasley A, Alter MJ (2000) Epidemiology of hepatitis C: Geographic differences and temporal trends. Semin Liver Dis 20: 1–16

    PubMed  CAS  Google Scholar 

  42. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA et al (1999) The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341: 556–562

    PubMed  CAS  Google Scholar 

  43. Yen T, Keeffe EB, Ahmed A (2003) The epidemiology of hepatitis C virus infection. J Clin Gastroenterol 36: 47–53

    Google Scholar 

  44. EI-Serag HB (2002) Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 35: S72–S78

    Google Scholar 

  45. Bosch FX, Ribes J, Borras J (1999) Epidemiology of primary liver cancer. Semin Liver Dis 19: 271–286

    PubMed  CAS  Google Scholar 

  46. El-Serag HB (2001) Global epidemiology of hepatocellular carcinoma. Clin Liver Dis 5: 87–107

    PubMed  CAS  Google Scholar 

  47. El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340: 745–750

    PubMed  CAS  Google Scholar 

  48. El-Serag HB (2002) Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 36 (5, Suppl 1): S74–S83

    PubMed  Google Scholar 

  49. Donato F, Boffetta P, Puoti M (1998) A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 75: 347–354

    PubMed  CAS  Google Scholar 

  50. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ (1991) Long-term clinical and histopathological follow-up of posttransfusion hepatitis. Hepatology 14: 969–974

    PubMed  Google Scholar 

  51. Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K, Kumada H, Kawanishi M (1993) A multivariate analysis of risk factors for hepatocellular carcinogenesis. Hepatology 18: 47–53

    PubMed  CAS  Google Scholar 

  52. Colombo M (1999) Hepatitis C virus and hepatocellular carcinoma. Baillieres Best Pract Res Clin Gastroenterol 13: 519–528

    PubMed  CAS  Google Scholar 

  53. Di Bisceglie AM (1997) Hepatitis C and hepatocellular carcinoma. Hepatology 26: 34S–38S

    PubMed  Google Scholar 

  54. Mourn B, Ekbom A, Vatn MH, Aadland E, Sauar J, Lygren I, Schulz T, Stray N, Fausa 0 (1997) Inflammatory bowel disease: re-evaluation of the diagnosis in a prospective population based study in south eastern Norway. Gut 40: 328–332

    Google Scholar 

  55. Loftus EV, Sandborn WJ (2002) Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am 31: 1–20

    PubMed  Google Scholar 

  56. Morita N, Toki S, Hirohashi T, Minoda T, Ogawa K, Kono S, Tamakoshi A, Ohno Y, Sawada T, Muto T (1995) Incidence and prevalence of inflammatory bowel disease in japan: nationwide epidemiological survey during the year 1991. J Gastroenterol 30 (Suppl 8): 1–4

    Google Scholar 

  57. Yoshida Y, Murata Y (1990) Inflammatory bowel disease in Japan: studies of epidemiology and etiopathogenesis. Med Clin North Am 74: 67–90

    PubMed  CAS  Google Scholar 

  58. Yang SK, Hong WS, Min YI, Kim HY, Yoo JH, Rhee PL, Rhee JC, Chang DK, Song IS, Jung SA et al (2000) Incidence of and prevalence of ulcerative colitis in the SongpaKangdong District, Seoul, Korea, 1986–1997. J Gastroenterol Hepatol 15: 1037–1042

    PubMed  CAS  Google Scholar 

  59. Wright JP, Froggatt J, O’Keefe EA, Ackerman S, Watermeyer S, Louw J, Adams G, Gird-wood AH, Burns DG, Marks IN (1986) The epidemiology of inflammatory bowel disease in Cape Town 1980–1984. S Afr Med J 70: 10–15

    PubMed  CAS  Google Scholar 

  60. Levin B (1992) Inflammatory bowel disease and colon cancer. Cancer 70: 1313–1316

    PubMed  CAS  Google Scholar 

  61. Gyde S, Prior P, Dew NJ, Saunders V, Waterhouse JA, Allan RN (1982) Mortality in ulcerative colitis. Gastroenterology 83: 36–43

    PubMed  CAS  Google Scholar 

  62. Sharan R, Schoen RE (2002) Cancer in inflammatory bowel disease: An evidence-based analysis and guide for physicians and patients. Gastroenterol Clin North Am 31: 237–254

    PubMed  Google Scholar 

  63. Eaden JA, Abrams KR, Mayberry JF (2001) The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48: 526–535

    PubMed  CAS  Google Scholar 

  64. Sugita A, Sachar DB, Bodian C, Ribeiro MB, Aufses AH, Greenstein AJ (1991) Colorectal cancer in ulcerative colitis. Influence of anatomical extent and age at onset on colitis-cancer interval. Gut 32: 167–169

    PubMed  CAS  Google Scholar 

  65. Markowitz J, McKinely M, Kahn E, Stiel L, Rosa J, Grancher K, Daum F (1997) Endoscopic screening for dysplasia and mucosal aneuploidy in adolescents and young adults with childhood onset colitis. Am J Gastroenterol 92: 2001–2006

    PubMed  CAS  Google Scholar 

  66. Bansal P, Sonnenberg A (1996) Risk for colorectalcoancer in inflammatory bowel disease. Am J Gastroenterol 91: 44–48

    PubMed  CAS  Google Scholar 

  67. Gillen CD, Walmsley RS, Prior P, Andrews HA, Allan RN (1994) Ulcerative colitis and Crohn’s disease: A comparison of the colorectal cancer risk in extensive colitis. Gut 35: 1590–1592

    PubMed  CAS  Google Scholar 

  68. Munkholm P, Langholz E, Davidsen M, Binder V (1993) Intestinal cancer risk and mortality in patients with Crohn’s disease. Gastroenterology 105: 1716–1723

    PubMed  CAS  Google Scholar 

  69. Weedon DD, Shorter RG, Ilstrup DM, Huizenga KA, Taylor WF (1973) Crohn’s disease and cancer. N Engl J Med 289: 1099–1103

    PubMed  CAS  Google Scholar 

  70. Bernstein CN, Blanchard JF, Kliewer E, Wajda A (2001) Cancer risk in patients with inflammatory bowel disease: A population-based study. Cancer 91: 854–862

    PubMed  CAS  Google Scholar 

  71. Ekbom A, Helmick C, Zack M, Adami HO (1990) Increased risk of large-bowel cancer in Crohn’s disease with colonic involvement. Lancet 336: 357–359

    PubMed  CAS  Google Scholar 

  72. Fireman Z, Grossman A, Lilos P, Hacohen D, Bar Meir S, Rozen P, Gilat T (1989) Intestinal cancer in patients with Crohn’s disease: A population study in central Israel. Scand J Gastroenterol 24: 346–350

    PubMed  CAS  Google Scholar 

  73. Gallop JH, Phillips SF, Melton III LJ, Zinsmeister AR. (1988) Epidemiologic aspects of Crohn’s disease: A population-based study in Olmsted County, Minnesota, 1943–1982. Gut 29: 49–56

    Google Scholar 

  74. Friedman S, Rubin PH, Bodian C, Goldstein E, Harpaz N, Present DH (2001) Screening and surveillance colonoscopy in chronic Crohn’s colitis. Gastroenterology 120: 820–826

    PubMed  CAS  Google Scholar 

  75. Johnson RD, Ausmn LM, Sehggal PK, King NW Jr (1996) A prospective study of the epidemiology of colitis and colon cancer in cotton top tamarins (Sanguinas oedipus). Gastroenterology 110: 102–115

    PubMed  CAS  Google Scholar 

  76. Berg DJ, Davidson N, Kuhn R, Muller W, Mennon S, Holland DG, Thompson-Snipes L, Leach MW, Rennick D (1995) Enterocolitis and colon cancer in interleukin 10 deficient mice are associated with abnormal cytokine production and CD 4’ TH-1 like responses. J Clin Invest 98: 1010–1020

    Google Scholar 

  77. Rudolph U, Finegold MJ, Ridge SS, Harriman GR, Srinivasan Y, Brabert P, Goyley G, Bradley A, Birnbaumer L (1995) Ulcerative colitis and adenocarcinoma of a colon in G alpha 1–2 deficient mice. Nat Genet 10: 143–150

    PubMed  CAS  Google Scholar 

  78. Cooper HS, Everley L, Chang WC, Pfeiffer G, Lee B, Murthy S, Clapper ML (2001) The role of mutant Apc in the development of dysplasia and cancer in the mouse model of dextran sulfate sodium-induced colitis. Gastroenterology 121: 1407–1416

    PubMed  CAS  Google Scholar 

  79. DeMeester TR, Wang CI, Wernly JA, Pellegrini CA, Little G, Klementschitsch P, Bermudez G, Johnson LF, Skinner DB (1980) Technique, indications, and clinical use of 24-hour esophageal pH monitoring. J Thorac Cardiovasc Surg 79: 656–670

    PubMed  CAS  Google Scholar 

  80. Johnsson F, Joelsson B, Gudmundsson K, Freiff L (1987) Symptoms and endoscopic findings in the diagnosis of gastroesophageal reflux disease. Scand J Gastroenterol 22: 714–718

    PubMed  CAS  Google Scholar 

  81. Cameron AJ, Zinsmeister AR, Ballard DJ, Carney JA (1990) Prevalence of columnar-lined (Barrett’s) esophagus: Comparison of population-based clinical and autopsy findings. Gastroenterology 99: 918–922

    PubMed  CAS  Google Scholar 

  82. Spechler SJ, Zeroogian JM, Antonioli DA, Wang HH, Goyal RK (1994) Prevalence of metaplasia at the gastro-esophageal junction. Lancet 344: 1533–1536

    PubMed  CAS  Google Scholar 

  83. Cameron AJ, Zinsmeister AR, Ballard DJ, Carney JA (1990) Prevalence of columnar-lined (Barrett’s esophagus). Gastroenterology 99: 918–922

    PubMed  CAS  Google Scholar 

  84. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr (1991) Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265: 1287–1289

    PubMed  CAS  Google Scholar 

  85. Bollschweiler E, Wolfgarten E, Gutschow C, Holscher AH (2001) Demographic varia-tions in the rising incidence of esophageal adenocarcinoma in white males. Cancer 92: 549–555

    PubMed  CAS  Google Scholar 

  86. Devesa SS, Blot WJ, Fraumeni JF Jr (1998) Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83: 2049–2053

    PubMed  CAS  Google Scholar 

  87. Bytzer P, Christensen PB, Damkier P, Vinding K, Seersholm N (1999) Adenocarcinoma of the esophagus and Barrett’s esophagus: a population-based study. Am J Gastroenterol 94: 86–91

    PubMed  CAS  Google Scholar 

  88. Falk GW (2002) Barrett’s esophagus. Gastroenterology 122: 1569–1591

    PubMed  Google Scholar 

  89. Lieberman DA, Oehlke M, Helfand M (1997) Risk factors for Barrett’s esophagus in community-based practice. Am J Gastroenterol 92: 1293–1297

    PubMed  CAS  Google Scholar 

  90. Singh P, Taylor RH, Colin-Jones DG (1994) Esophageal motor dysfunction and acid exposure in reflux esophagitis are more severe if Barrett’s metaplasia is present. Am J Gastroenterol 89: 349–356

    CAS  Google Scholar 

  91. Oberg S, DeMeester TR, Peters JH, Hagen JA, Nigro JJ, DeMeester SR, Theisen J, Campos GM, Crookes PF (1999) The extent of Barrett’s esophagus depends on the status of the lower esophageal sphincter and the degree of esophageal acid exposure. J Thorac Cardiovasc Surg 117: 572–580

    PubMed  CAS  Google Scholar 

  92. Lagergren J, Bergstrom R, Lindgren A, Nyren 0 (1999) Symptomatic gastroesophageal reflux disease as a risk factor for esophageal adenocarcinoma. N Engl J Med 340: 825–831

    PubMed  CAS  Google Scholar 

  93. Farrow DC, Vaughan TL, Sweeney C, Gammon MD, Chow WH, Risch HA, Stanford JL, Hantsen PD, Mayne ST, Schoenberg JB et al (2000) Gastroesophageal reflux disease, use of H2 receptor antagonists and risk of esophageal and gastric cancer. Cancer Causes Control 11: 231–238

    PubMed  CAS  Google Scholar 

  94. Lowenfels AB, Maisonneuve P (2002) Epidemiologic and etiologic factors of pancreatic cancer. Hematol Oncol Clin of North Am 16: 1–16

    Google Scholar 

  95. Greenlee RT, Murray T, Bolden S, Wingo PA (2000) Cancer statistics 2000. CA Cancer J Clin 50: 7–33

    CAS  Google Scholar 

  96. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Mariotto A, Feuer EJ, Edwards BK (2000) Seer Cancer Statistics Review, 1973–1996. National Cancer Institute, Bethesda, MD

    Google Scholar 

  97. Gold EB, Gordis L, Diener MD, Seltser R, Boitnott JK, Bynum TE, Seltser R, Boitnott JK, Bynum TE, Hutcheon DF (1985) Diet and other risk factors for cancer of the pancreas. Cancer 55: 460–467

    PubMed  CAS  Google Scholar 

  98. Mack TM, Yu MC, Hanisch R, Henderson BE (1986) Pancreas cancer and smoking, beverage consumption and past medical history. J Natl Cancer Inst 76: 49–60

    PubMed  CAS  Google Scholar 

  99. Farrow DC, Davis S (1990) Risk of pancreatic cancer in relation to medical history and use of tobacco, alcohol and coffee. Int J Cancer 45: 816–820

    PubMed  CAS  Google Scholar 

  100. Jain M, Howe GR, St Louis P, Miller AB (1991) Coffee and alcohol as determinants of risk of pancreatic cancer: a case-control study from Toronto. Int J Cancer 47: 384–389

    PubMed  CAS  Google Scholar 

  101. Kalapothaki V, Tzonou A, Hsieh CC, Toupadaki N, Trichopoulos D (1993) Tobacco,ethanol, coffee, pancreatitis, diabetes mellitus, and cholelithiasis as risk factors for pancreatic carcinoma. Cancer Causes Control 4: 1433–1437

    Google Scholar 

  102. Lowenfels AB, Maisonneuve P, Cavallini G, Ammann RW, Lankisch PG, Andersen JR, Ammann RW, Lankisch PG, Andersen JR, Dimagno EP et al (1993) Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med 328: 1433–1447

    PubMed  CAS  Google Scholar 

  103. Talamini G, Falconi M, Bassi C, Sartori N, Salvia R, Caldiron E, Frulloni L, Di Francesco V, Vaona B, Bovo P et al (1999) Incidence of cancer in the course of chronic pancreatitis. Am J Gastroenterol 94: 1253–1260

    PubMed  CAS  Google Scholar 

  104. Mostafa MH, Sheweita A, O’Connor PJ (1999) Relationship between schistosomiasis and bladder cancer. Clin Microbiol Rev 12: 97–111

    PubMed  CAS  Google Scholar 

  105. El-Sebai I (1977) Parasites in the etiology of cacaner; bilharziasis and bladder cancer. CA Cancer J Clin 27: 100–106

    CAS  Google Scholar 

  106. Al-Shukri SM, Alwan H, Nayef M, Rahman AA (1987) Bilharziasis in malignant tumors of the urinary bladder. Br J Urol 59: 59–62

    PubMed  CAS  Google Scholar 

  107. Elem B, Purohit R (1983) Carcinoma of urinary bladder in Zambia: a quantitative estimate of Schistosoma haematobium infection. Br J Urol 55: 275–278

    PubMed  CAS  Google Scholar 

  108. Lucas SB (1982) Squamous cell carcinoma of the bladder and Schistosomiasis. East Afr Med J 59: 345–351

    PubMed  CAS  Google Scholar 

  109. El-Sebai I (1977) Parasites in the etiology of cancer; bilharziasis and bladder cancer. CA Cancer J Clin 27: 100–106

    CAS  Google Scholar 

  110. Kuntz RE, Cheever AW, Myers BJ (1972) Proliferative lesions of the urinary bladder of non-human primates infected with Schistosoma haematobium. J Natl Cancer Inst 48: 223–235

    CAS  Google Scholar 

  111. Wagner JC, Sleggs EA, Marchand P (1960) Diffuse pleural mesothelioma and asbestos in the North Western Cape Province. Br J Ind Med 17: 260–270

    PubMed  CAS  Google Scholar 

  112. Selikoff IJ, Churg J, Hammond EC (1964) Asbestos exposure and neoplasia. JAMA 188: 22–26

    PubMed  CAS  Google Scholar 

  113. Lanphear BP, Buncher CR (1992) Latent period for malignant mesothelioma of occupational origin. J Occupat Med 34: 718–721

    CAS  Google Scholar 

  114. Enterline PE, Henderson VL (1987) Geographic patterns for female pleural mesothelioma deaths for 50 states. J Natl Cancer Inst 79: 31–37

    PubMed  CAS  Google Scholar 

  115. Walker AM, Loughlin JE, Freidlander ER, et al (1983) Projections of asbestos-related disease 1980–2009. J Occupat Med 25: 409–425

    CAS  Google Scholar 

  116. Peto J, Hodgson JT, Mathews FE, Jones JR (1995) Continuing increase in mesothelioma mortality in Britain. Lancet 345: 535–539

    PubMed  CAS  Google Scholar 

  117. Funkhouser EM, Sharp GB (1995) Aspirin and reduced risk of esophageal carcinoma. Cancer 76: 1116–1169

    PubMed  CAS  Google Scholar 

  118. Aker K, Ekstsrom AM, Signorello LB, Hansson LE, Nyren O (2001) Aspirin and risk of gastric cancer: a population based case-control studying Sweden. Br J Cancer 84: 965–968

    Google Scholar 

  119. Giovannucci E, Eagan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willet WC, Speizer FE (1995) Aspirin and risk of colorectal cancer in women. N Engl J Med 333: 609–614

    PubMed  CAS  Google Scholar 

  120. Giovannucci E, Rimm EG, Stampfer MJ, Colditz GA, Ascherio A, Willett WC (1994) Aspirin use and the risk of colorectal cancer and adenoma in male health professionals. Ann Intern Med 121: 241–246

    PubMed  CAS  Google Scholar 

  121. Thun MJ, Namboodiri MM, Dealth CW Jr (1991) Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325: 1593–1596

    PubMed  CAS  Google Scholar 

  122. Schreinemachers DM, Everson RB (1994) Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5: 138–146

    PubMed  CAS  Google Scholar 

  123. Castelao JE, Yuan JM, Gago-Dominguez M, Yu MC, Ross RK (2000) Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer 82: 1364–1369

    PubMed  CAS  Google Scholar 

  124. Harris RE, Kasbari S, Farrar WB (1999) Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol Rep 6: 71–73

    PubMed  CAS  Google Scholar 

  125. Steinbach G, Lynch PM, Phillips RKS, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T (2000) The effect of celecoxib, a cylooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342: 1946–1952

    PubMed  CAS  Google Scholar 

  126. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL et al (2003) A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348: 883–890

    PubMed  CAS  Google Scholar 

  127. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, Mckeown-Eyssen G, Summers RW, Rothstein R, Burke CA et al (2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348: 891–899

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Drexel University College of Medicine, Drexel University, 245 N 15th Street, Philadelphia, PA, 19102-1192, USA

    Jong H. Nam & Sreekant Murthy

Authors
  1. Jong H. Nam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sreekant Murthy
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. TAP Pharmaceuticals, 675 North Field Dr., Lake Forest, IL, 60045, USA

    Douglas W. Morgan

  2. IPF PharmaCeuticals, Feodor-Lynen-Strasse 31, Hannover, 30625, Germany

    Ulf J. Forssmann

  3. Oncology Research, Centocor, 200 Great Valley Parkway, Malvern, PA, 19355, USA

    Marian T. Nakada

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Basel AG

About this chapter

Cite this chapter

Nam, J.H., Murthy, S. (2004). Chronic inflammation and cancer in various organ systems. In: Morgan, D.W., Forssmann, U.J., Nakada, M.T. (eds) Cancer and Inflammation. Progress in Inflammation Research. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-7861-6_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-7861-6_1

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-9600-9

  • Online ISBN: 978-3-0348-7861-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation